Infliximab and Infliximab-dyyb Activity and Neutralizing Antibody

Patient: [redacted]
DOB: [redacted] Age: [redacted] Gender: [redacted]
Patient Identifiers: [redacted]

Visit Number (FIN): [redacted]

Client: [redacted]

Physician: [redacted]

ARUP Test Code: 2008320

Collection Date: 11/13/2017
Received in lab: 11/14/2017
Completion Date: 11/14/2017

Patient History *

Collection Date	Infliximab Activity (IFX) ug/mL	Neutralizing Antibody (IFX NAb) Titer	Accession Number
11/13/2017	1.62	Not Detected	17-317-104863
10/16/2017	Not Detected	1:39	17-289-108812
8/25/2017	Not Detected	1:38	17-237-109252
6/14/2017	Not Detected	Not Detected	17-165-129059
4/7/2017	Not Detected	1:77	17-097-107271
1/9/2017	5.16	Not Detected	17-009-109445
12/16/2016	Not Detected	Not Detected	16-351-101811
10/27/2016	>40.00	Not Detected	16-301-116412



ARUP LABORATORIES | 500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: (801) 583-2787 | toll free: (800) 522-2787 | **www.aruplab.com**
JULIO C. DELGADO, MD, MS | Director of Laboratories

Chart continues on following page(s)

Cutoff values are 0.65 ug/mL for infliximab and 1:20 for antidrug antibody (NAb).

*Consecutive test results are displayed on this chart; however, this result set may be incomplete due to variations in the demographic information submitted for prior tests. If the information on this chart appears incomplete, please consult this patient's prior charts.

Interpretive Comments

Interpretive Data: This test measures the capacity of infliximab to neutralize TNF-alpha activity. Additionally, infliximab neutralizing antibodies (NAb) are titered (reporting the highest dilution of patient sera in which NAb activity is detected).

This test is used to evaluate secondary response failures to infliximab therapy. Secondary response failure is defined as loss of clinical response after initial improvement of clinical signs and symptoms. Therapeutic decision should rest on both the clinical response and the knowledge of the fate of the drug including the emergence of immunogenicity in individual patients.

Circulating infliximab levels have been shown to vary considerably between patients. These differences relate to route and frequency of administration and patient-related features such as age, gender, weight, drug metabolism, and concomitant medications such as methotrexate and other immunosuppressants.

IF Infliximab Activity is...	AND Infliximab Neutralizing Antibody Titer is...	THEN...
Not Detected	Not Detected	A higher dosage of infliximab or shortening the dosing interval may be appropriate.
Not Detected	1:20 or greater	A change to another anti-TNF-alpha drug may be appropriate.
0.65 ug/mL or greater	Not Detected	A change to another type of therapy (not targeting TNF-alpha) may be appropriate.
0.65 ug/mL or greater	1:20 or greater	Repeat testing is suggested to rule out decreasing infliximab activity and/or increasing infliximab neutralizing antibodies.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS.

ARUP LABORATORIES | 500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: (801) 583-2787 | toll free: (800) 522-2787 | **www.aruplab.com**
JULIO C. DELGADO, MD, MS | Director of Laboratories

END OF CHART